Adverse events following immunization associated with coronavirus disease 2019 (COVID-19) vaccines: A descriptive analysis from VigiAccess

References

• Rappuoli R, Pizza M, Del Giudice G, De Gregorio E. Vaccines, new opportunities for a new society. Proc Natl Acad Sci USA. 2014;111(34):1–6. doi:10.1073/pnas.1402981111.
   Web of Science ®Google Scholar
• Murphy SL, Xu J, Kochanek KD. Deaths, final data for 2010. Natl Vital Stat Rep. 2013;61:1–117.
   PubMedGoogle Scholar
• World Health Organization. Immunization safety surveillance guidelines for immunization programme managers on surveillance of adverse events following immunization. 2nd ed. Geneva: World Health Organization Western pacific region. WHO; 2013.
   Google Scholar
• Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein–polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9(3):213–220. doi:10.1038/nri2494.
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavon AB, Urwin R, Grays SJ, Andrews NJ, Clarke SC, Walker AM, Evans MR, Kroll JS, Neal KR, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197(5):737–743. doi:10.1086/527401.
   PubMed Web of Science ®Google Scholar
• Rodrigues CMC, Plotkin SA. Impact of vaccines; health, economic and social perspectives. Front Microbiol. 2020;11:1526.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Nieminen H, Rinta-Kokko H, Ruokokski E, Puumalainen T, Borys D, Lommel P, Traskine M, Moreira M, et al. Effect of pneumococcal haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3–4 trial. Lancet Infect Dis. 2014;14(3):205–212. doi:10.1016/S1473-3099(13)70338-4.
   PubMed Web of Science ®Google Scholar
• Bogler Y, Wong RJ, Gish RG. Epidemiology and natural history of chronic hepatitis B virus infection. In: Kao J-H, Chen D, editors. Hepatitis B Virus and Liver Disease. Berlin: Springer; 2018. p. 63–89.
   Google Scholar
• Bloom DE, Canning D, Weston M. The value of vaccination. World Econ. 2005;6:15–16.
   Google Scholar
• Deogaonkar R, Hutubessy R, van der Putten I, Evers S, Jit M. Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries. BMC Public Health. 2012;12:878. doi:10.1186/1471-2458-12-878.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine (US). Committee to Study New Research on Vaccines. In: Stratton KR, Howe CJ, Johnston RB, Jr., editors. Research strategies for assessing adverse events associated with vaccines: a workshop summary. Washington (DC): National Academics Press (US); 1994. CLINICAL TRIALS
   Google Scholar
• One Africa. Data dive: the astoundingly unequal vaccine roll-out, 2021. [accessed 2021 Dec 31]. https://www.one.org/Africa/issues/covid-19-tracker/explore-vaccines/.
   Google Scholar
• Council for International Organizations of Medical Sciences, CIOMS. Definition and application of terms for vaccine pharmacovigilance, report of CIOMS/WHO working group on vaccine pharmacovigilance. Geneva; 2012.
   Google Scholar
• Cashman P, Macartner K, Khandaker G, King C, Gold M, Durrheima DN. Participant centred active surveillance of adverse events following immunization: a narrative review. Int Health. 2017;9(3):164–176. doi:10.1093/inthealth/ihx019.
   PubMed Web of Science ®Google Scholar
• Li R, McNeil MM, Pickering S, Pemberton MR, Duran LL, Collins LC, Nelson MR, Engler RJM. Military healthcare providers reporting of adverse events following immunization to the vaccine adverse event reporting system. Mil Med. 2014;179(4):435–441. doi:10.7205/MILMED-D-13-00391.
   PubMed Web of Science ®Google Scholar
• Parrella A, Gold M, Braunack-Mayer A, Baghurst P, Marshall H. Consumer reporting of adverse events following immunization (AEFI): Identifying predictors of reporting an AEFI. Hum Vaccin Immunother. 2014;10(3):747–754. doi:10.4161/hv.27459.
   PubMed Web of Science ®Google Scholar
• Hu Y, Li Q, Lin L, Chen E, Chen Y, Qi X. Surveillance of adverse events following immunization from 2008 to 2011 in Zhejiang province, China. Clini Vaccine Immunol. 2013;20(2):211–217. doi:10.1128/CVI.00541-12.
   PubMedGoogle Scholar
• Amodio E, Minutolo G, Casuccio A, Constantino C, Graziano G, Mazzucco W, Pieri A, Vitale F, Zarcone M, Restivo V. Adverse reactions to anti-SARS-CoV-2 vaccine: a prospective cohort study based on an active surveillance system. Vaccines. 2022;10(3):345. doi:10.3390/vaccines10030345.
   Web of Science ®Google Scholar
• Stefanizzi P, De Nitto S, Patano F, Bianchi FP, Ferorelli D, Stella P, Ancona D, Bavaro V, Tafuri S. Post-marketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospecive study in apulia region (ITALY), 2009–2017. Hum Vaccin Immunother. 2022 Aug 2;16(8):1875–1883. doi:10.1080/21645515.2019.1704124. Epub 2020 Feb 10. PMID: 32040350; PMCID: PMC7482746.
   Web of Science ®Google Scholar
• Wetsman N. WHO declares the outbreak of the new coronavirus is a pandemic. 2020 Mar 11 [accessed 2021 Oct 25]. https://www.theverge.com/2020/3/11/2/1156325/coronavirus-pandemic-who-declares-covid-19-outbreak-global-hini.
   Google Scholar
• Choudhary OP, Priyanka SI, Rodriguez-Morales AJ, Rodriguez-Morales AJ. Second wave of COVID-19 in India: dissection of the causes and lessons learnt. Travel Med Infect Dis. 2021;43:102126. doi:10.1016/j.tmaid.2021.102126.
   PubMed Web of Science ®Google Scholar
• Rabaan AA, Al-Ahmed SH, Sah R, Tiwari R, Yatoo MI. Patel SK, Pathak M, Malik YS, Dhama K, Singh KP, et al. SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. Ann Clin Microbiol Antimicrob. 2020;19(1):40. doi:10.1186/s12941-020-00384-w.
   PubMed Web of Science ®Google Scholar
• McGill COVID-19 Vaccine Tracker Team. 2021. Vaccines candidates by trial phase. [accessed 2021 Nov 15]. http://covid19.trackvaccines.org/vaccines/?fbclid=IwAR0rJdUx1T1j9Ta1YCJzwvnqm6MW1uN2wwWtnuDP0GW6YvKLh3nW-Ex0ZKU.
   Google Scholar
• Bakhshandeh B, Jahanafrooz Z, Abbasi A, Goli MB. Sadeghi M, Mottaqi MS, Zamani M. Mutations in SARS-CoV-2; consequences in structure, function and pathogenicity of the virus. Microb Pathog. 2021;154:104831. doi:10.1016/j.micpath.2021.104831.
   PubMed Web of Science ®Google Scholar
• Peterson E, Ntoumi F, Hui DS, Abubakar A, Kramer LD, Obiero C, Tambyah PA, Blumberg L, Yapi R, Al-Abri S, et al. Emergence of new SARS-CoV-2 variant of concern omicron (B.1.1.529)-highlights Africa’s research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. Int J Infect Dis. 2022;114:268–272. doi:10.1016/j.ijid.2021.11.040.
   PubMed Web of Science ®Google Scholar
• Kimball S. WHO says COVID omicron detected in 38 countries, early data suggests it’s more contagious than delta. [accessed 2021 Dec 7]. https://www.cnbc.com/2021/12/03/who-says—omicron-covid-variant-has-spread-to-38-countries.html.
   Google Scholar
• WHO 2nd global consultation on assessing the impact of SARS-CoV-2 variants of concern on public health interventions. [accessed 2021 Dec 2]. https://www.who.int/publications/m/item/2nd-global-consultation-on-on-public-health-interventions.
   Google Scholar
• Centers for disease control and prevention, omicron variant: what you need to know. [accessed 2021 Dec 7]. https://www.cdc.gov/coronavirus/2019-ncov/variant.html.
   Google Scholar
• Danabal KGM, Magesh SS, Saravanan S, Gopichandran V. Attitude towards COVID 19 vaccines and vaccine hesitancy in urban and rural communities in Tamil Nadu, India – a community based survey. BMC Health Serv Res. 2021;21(1):994. doi:10.1186/s12913-021-07037-4.
   PubMed Web of Science ®Google Scholar
• Dhama K, Sharun K, Tiwari R, Dhawan M, Emran TB, Rabaan AA, Alhumaid S. COVID-19 vaccine hesitancy-reasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic. Hum Vaccin Immunother. 2021;17(10):3495–3499. doi:10.1080/21645515.2021.1926183.
   PubMed Web of Science ®Google Scholar
• World Health Organization. VigiAccess database. [accessed 2021 Nov 10]. https://www.vigiaccess.org.
   Google Scholar
• Centers for disease control and prevention, CDC recommends pediatric COVID-19 vaccine for children 5-11 years. [accessed 2021 Dec 7]. https://www.cdc.gov/media/releases/2021/s1102-PediatricCOVID-19Vaccine.html.
   Google Scholar
• World Health Organization. The causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification, WHO/HIS/EMP/QSS. [accessed 2021 Dec 20]. https://www.who.int/vaccine_safety/publications/gvs_aefi/en/.
   Google Scholar
• Singh AK, Wagner AL, Joshi J, Carlson BF, Aneja S, Boulton ML. Causality assessment of serious and severe adverse events following immunization in India: a 4 year practical experience. Expert Rev Vaccines. 2018;17(6):555–562. doi:10.1080/14760584.2018.1484285.
   PubMed Web of Science ®Google Scholar
• USA today, fact check: post misleads on WHO’s VigiAccess tool. [accessed 2021 Dec 8]. https://www.usatoday.com/story/news/factcheck/2021/10/15/fact-check-post-misleads-whos-vigiaccess-tool/6101202001/.
   Google Scholar
• Gidudu JF, Shaum A, Dodoo A, Bosomprah S, Bonsu G, Amponsa-Achiano K, Darko DM, Sabblah G, Opare J, Nyaku M, et al. Barriers to healthcare workers reporting adverse events following immunization in four regions of Ghana. Vaccine. 2020;38(5):1009–1014. doi:10.1016/j.vaccine.2019.11.050.
   PubMed Web of Science ®Google Scholar
• Yamoah P, Bangalee V, Oosthuizen F. Knowledge and perceptions of adverse events following immunization among healthcare professionals in Africa: a case study from Ghana. Vaccines. 2019;7(1):28. doi:10.3390/vaccines7010028.
   Web of Science ®Google Scholar
• Centres for Disease Control and Prevention (CDC). Coronavirus disease 2019 (COVID-19): latest updates on the COVID-19 crises in Africa CDC. 2021 [accessed 2021 Dec 11]. https://africacdc.org/covid-19/.
   Google Scholar
• Idris IO, Ayeni GO, Adebisi YA. Why many African countries may not achieve the 2022 COVID-19 vaccination coverage target. Trop Med Health. 2022;50(1):15. doi:10.1186/s41182-022-00407-6.
   PubMed Web of Science ®Google Scholar
• Cunha MP, Dórea JG, Marques RC, Leǻo RS. Vaccine adverse events reported during the first ten years (1998-2008) after introduction in the state of Rondonia, Brazil. Biomed Res Int. 2013;853083.
   Google Scholar
• Centers for Disease Control and Prevention. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNtech COVID-19 vaccine-United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70:46–51.
   PubMed Web of Science ®Google Scholar
• Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNtech COVID-19 vaccine. Jama. 2021;325(8):780–781. doi:10.1001/jama.2021.0600.
   PubMed Web of Science ®Google Scholar
• Joshi RK, Muralidharan CG, Gulati DS, Mopagar V, Dev JKP, Kuthe S, Rather AA, Sahoo AK. Higher incidence of reported adverse events following immunization (AEFI) after first dose of COVID-19 vaccine among previously infected health care workers. Med J Armed Forces India. 2021;77(Suppl 2):S505–7. doi:10.1016/j.mjafi.2021.05.011.
   PubMedGoogle Scholar
• Harris T, Nair J, Fediurek J, Deeks SL. Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012-2015. Vaccine. 2017;35(19):2600–2604. doi:10.1016/j.vaccine.2017.03.035.
   PubMed Web of Science ®Google Scholar
• Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015;33(36):4398–4405. doi:10.1016/j.vaccine.2015.07.035.
   PubMed Web of Science ®Google Scholar
• Puzio A. Why is there such a gender gap in COVID-19 vaccination rates? [accessed 2021 Dec 8]. https://fivethirty.com/features/why-is-there-such-a-gender-gap-in-covid-19-vaccination-rates/.
   Google Scholar
• Indian Society of Nephrology. Technical aspects of vaccine administration. Indian J Nephrol. 2016;26(Suppl 1):S29–30.
   Google Scholar
• Kartoglu U, Milstien J. Tools and approaches to ensure quality of vaccines throughout the cold chain. Expert Rev Vaccines. 2014;13(7):843–854. doi:10.1586/14760584.2014.923761.
   PubMed Web of Science ®Google Scholar